Improved outcome with high-dose rituximab (HD-R) with G/GM-CSF and autologous stem cell transplantation (ASCT) for relapsed aggressive B-cell non-Hodgkin's lymphomas (NHL): The impact of histologies of follicular (FL) origin.

被引：0
|
作者：
Khouri, IF [1 ]
Saliba, RM [1 ]
Acholonu, S [1 ]
Okoroji, GJ [1 ]
Hosing, C [1 ]
Fayad, L [1 ]
Couriel, DR [1 ]
Pro, B [1 ]
Giralt, S [1 ]
Andersson, B [1 ]
Younes, A [1 ]
McLaughlin, P [1 ]
Champlin, RE [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2716
引用
收藏
页码：735A / 736A
页数：2
相关论文
共 50 条
  • [31] Ofatumumab, Very Late Antigen 4 (VLA4), and Dendritic Cells in Patients Undergoing Autologous Peripheral Blood Stem Cell (PBSC) Mobilization and Transplantation (ASCT) for Relapsed b-Cell Non-Hodgkin's Lymphomas (NHL)
    Khouri, Issa F.
    Gao, Hui
    Milton, Denai R.
    Korbling, Martin
    Ledesma, Celina
    Fayad, Luis E.
    Jabbour, Elias J.
    Gulbis, Alison M.
    Reuben, James M.
    BLOOD, 2017, 130
  • [32] Prognostic significance of bcl-2 protein expression in predicting the outcome of high-dose therapy (HDT) and autologous stem cell transplant (ASCT) in patients with diffuse large B-cell (DLBCL) non-Hodgkin's lymphoma (NHL).
    Nademanee, A
    Arber, D
    Dagis, A
    Molina, A
    Fung, HC
    Rodriguez, R
    Amrita, K
    Zain, J
    Popplewell, L
    Snyder, DS
    O'Donnell, M
    Parker, PM
    Stein, A
    Bhatia, R
    Smith, E
    Nakamura, R
    Smith, D
    Forman, SJ
    BLOOD, 2003, 102 (11) : 738A - 739A
  • [33] Phase II trial of rituximab as adjuvant therapy to high dose chemotherapy and peripheral blood stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphomas.
    Horwitz, SM
    Negrin, RS
    Stockerl-Goldstein, KE
    Johnston, LJ
    Shizuru, JA
    Stuart, MJ
    Breslin, S
    Blume, KG
    Horning, SJ
    BLOOD, 2001, 98 (11) : 862A - 862A
  • [34] High-dose chemotherapy, autologous stem cell transplantation (ASCT) and ex vivo lymphoma cell purging using B-cell high density microparticles (HDM) cell separation system:: PCR does not accurately predict disease recurrence in patients (pts) with follicular non-Hodgkin's lymphoma (FL).
    Friedberg, JW
    Li, SG
    Kim, H
    Neuberg, D
    Boyd, K
    Daley, H
    Fisher, DC
    Monroy, R
    Spitzer, TR
    Freedman, AS
    BLOOD, 2002, 100 (11) : 835A - 835A
  • [35] Phase I trial of yttrium 90 ibritumomab tiuxetan (90Y-RIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL)
    Swinnen, L. J.
    Flinn, I. W.
    Kahl, B. S.
    Frey, E.
    Rogers, K.
    Jung, M.
    Jacene, H.
    Wahl, R. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Phase I trial of 90Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation
    Vose, Julie M.
    Bierman, Philip J.
    Loberiza, Fausto R., Jr.
    Bociek, Robert G.
    Matso, Daniel
    Armitage, James O.
    LEUKEMIA & LYMPHOMA, 2007, 48 (04) : 683 - 690
  • [37] High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma:: results of a multicenter phase II study
    Josting, A
    Sieniawski, M
    Glossmann, JP
    Staak, O
    Nogova, L
    Peters, N
    Mapara, M
    Dörken, B
    Ko, Y
    Metzner, B
    Kisro, J
    Diehl, V
    Engertl, A
    ANNALS OF ONCOLOGY, 2005, 16 (08) : 1359 - 1365
  • [38] Front-line double high dose chemotherapy (HDCT) with DICEP-BEAM and autologous stem cell transplantation (ASCT) for poor prognosis aggressive non-Hodgkin's lymphoma (NHL)
    Stewart, D
    Valentine, K
    Balogh, A
    Morris, D
    Brown, C
    Jones, A
    Russell, JA
    ANNALS OF ONCOLOGY, 2005, 16 : 99 - 99
  • [39] High-dose radioimmunotherapy/chemotherapy and autologous stem cell transplantation (ASCT) for poor risk and relapsed CD20+non-Hodgkin's lymphoma (NHL): Early feasibility report.
    Raubitschek, A
    Nademanee, A
    Molina, A
    Rodriguez, R
    White, C
    Forman, S
    BLOOD, 2000, 96 (11) : 374B - 375B
  • [40] R-DHAP - sequential high-dose chemotherapy with autologous stem cell support in combination with the anti-CD20 antibody Rituximab in relapsed aggressive non-Hodgkin lymphoma
    Sieniawski, M
    Staak, JO
    Scheuss, H
    Glossmann, JP
    Diehl, V
    Engert, A
    Josting, A
    BONE MARROW TRANSPLANTATION, 2004, 33 : S247 - S248
12345